Threat Behind Patents on Antineoplastons: Burzynski, The Movie

[Guest guest]

Hi Readers and Acytivists,

Last night (6/4/10), I saw Burzynski, the movie at the Cinema Village at 22

East 12th Street in NY City.

The film will be playing until Thursday June 10. Times are 1:00pm, 3:10,

5:15, 7:25 and 9:40,

It is worth seeing.

_http://cinemavillage.com/chc/cv/_ (http://cinemavillage.com/chc/cv/)

The movie movingly recounts the experiences of many of the patients trying

to access Dr.Burzynski's antineoplastons, that have had remarkable success

in treating cancers with a minimum of side effects.

The movie highlights the many Complete Responses, defined by the National

Cancer Institute (NCI) as complete elimination of the tumor on imaging for

at least 4 weeks. While these numbers are impressive, the inclusion of data

on Partial Response, defined by NCI as greater than 50% tumor size on

imaging for at least 4 weeks, and Stable Disease defined by NCI as less than

50%

in tumor size for at least 12 weeks.

While totals vary depending on the trial. Totals of Complete

Response+Partial Respons=Stable Disease range from over 66% to 92%. Far and way

the best

results for Cancer treatments.

Statistics on Clinical Trial Results for Antineoplastons as reported by the

Burzynski Patient Group.

_http://www.burzynskipatientgroup.org/cancernews.html_

(http://www.burzynskipatientgroup.org/cancernews.html)

One of the less dramatic portions of the movie, details the sordid history

of numerous apparently stolen patents being filed for anti-neoplastons.

While motivations are speculative here, the behavior of at least one other

pharmaceutical company, Merck, in filing patents on the combination of

Mevacor and Coenzyme Q10 is instructive. Coenzyme Q10 is essential for heart

health, it is destroyed by statin drugs, and Mevacor is Merck's statin drug.

After Merck patented this formula, giving it exclusive rights to use it,

the company just never brought out the combination of Mevacor and Coenzyme

Q10, causing many patients to aggravate their heart disease and thereby

blocking any other company from coming out with this combination.

By patenting antineoplastons and refusing to bring out the drug, if

Dr.Burzynski could be stopped, the conventional cancer treatment industry could

continue using toxic, but highly profitable chemotherapy and

radiation. Therein lies the hidden significance of a passing economic

maneuver.

Arnold